Dr. Allen Davidoff, PhD
Dr. Allen W. Davidoff, Ph.D. (10 years drug development ), Formerly, Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (7 yrs). Previously, Senior Scientist and Head of Pharmacology at Cardiome Pharma and has 10 years of drug development experience with a broad clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug (“IND”) applications or supplemental IND’s, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA. Allen Davidoff has previously served a Director of Neurogenesis (predescessor of Stem Cell Therapeutics Corp.), and currently Patient Stem Cell Resource Inc.
Dr. Alan Moore, PhD
Dr. Alan F. Moore, Ph.D. , has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D. During his esteemed career, he has completed 11 investigational new drug (“IND”) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications.
Mr. Rowlands is the current Chairman and Chief Executive Officer of Eurocontrol Technics Group, a TSXV listed company that is focused on the acquisition and development of certification and authentication technologies. Prior to forming Eurocontrol, Mr. Rowlands worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, a leading Canadian biotechnology company and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.